Calhoun D A, Li Y, Christensen R D
Department of Pediatrics, University of Florida College of Medicine, Gainesville 32610-0296, USA.
Pediatr Res. 1996 Dec;40(6):872-5. doi: 10.1203/00006450-199612000-00017.
Administration of large doses of recombinant granulocyte colony-stimulating factor (rG-CSF) to mice results in diminished erythropoiesis. Hyporegenerative anemia does not occur in adult humans as a consequence of treatment with rG-CSF, but it is not clear whether this will be a problem in neonates. Because rG-CSF is currently being tested as a treatment for neutropenia in neonates, we assessed the possibility that such treatment will diminish their erythropoiesis. To do this, we added rG-CSF, in vitro, to clonogenic cultures of hematopoietic progenitors obtained from the bone marrow and liver of seven human fetuses and from the umbilical cord blood of five term and five preterm infants. The range of rG-CSF concentrations tested (0.1-10.0 ng/mL) included the peak concentrations measured in the blood of neonates receiving rG-CSF treatment on experimental protocols. Inclusion of rG-CSF in the cultures did not diminish clonal maturation of fetal erythroid (erythroid colony-forming and burst-forming unit) progenitors, nor did it reduce the number of normoblasts generated per erythroid progenitor cell colony. On the basis of these studies we predict that administration of rG-CSF to neonates will not result in down-modulation of erythropoiesis.
给小鼠注射大剂量重组粒细胞集落刺激因子（rG-CSF）会导致红细胞生成减少。成年人类接受rG-CSF治疗不会出现再生低下性贫血，但尚不清楚这在新生儿中是否会成为问题。由于目前正在对rG-CSF作为新生儿中性粒细胞减少症的治疗方法进行测试，我们评估了这种治疗会减少其红细胞生成的可能性。为此，我们在体外将rG-CSF添加到从7例人类胎儿的骨髓和肝脏以及5例足月儿和5例早产儿的脐带血中获取的造血祖细胞克隆培养物中。所测试的rG-CSF浓度范围（0.1 - 10.0 ng/mL）包括在接受rG-CSF治疗的新生儿血液中测得的峰值浓度。在培养物中加入rG-CSF不会减少胎儿红系（红系集落形成单位和爆式集落形成单位）祖细胞的克隆成熟，也不会减少每个红系祖细胞集落产生的正成红细胞数量。基于这些研究，我们预测给新生儿注射rG-CSF不会导致红细胞生成的下调。
